Eyal Talor Increases Stake in CVM with Recent Share Purchase

Eyal Talor, the Chief Scientific Officer of CVM, made a notable purchase of company shares on June 30, 2026. Talor acquired 2,307 shares at a price of $1.04 each, amounting to a total investment of $2,399.28. This insider transaction was not part of a pre-planned trading program, indicating a direct decision to increase his stake in the company.

Other Institutional Activity in CVM

Several institutional investors have also been active with CVM shares. Vanguard Capital Management LLC opened a new position with 243,645 shares valued at about $782,100. MAI Capital Management increased its holdings by 1,557 shares to reach a total of 91,280 shares, valued at approximately $293,009, marking a 1.7% increase. Geode Capital Management, LLC added 6,128 shares, bringing its total to 85,311 shares, worth around $273,988, reflecting a 7.7% increase. Meanwhile, Vanguard Fiduciary Trust Co also initiated a new position with 49,036 shares valued at $157,406.

CEL-SCI Corporation Stock Down 33.3%

Shares of CVM traded near $1.04 on Wednesday. While specific market cap and P/E ratio data are not available, the recent insider activity suggests a level of confidence from company executives. Analysts have been active with CVM, with EF Hutton initiating coverage with a 'buy' rating and a price target of $10.00 back on February 17, 2023.

Insider Buying and Selling at CEL-SCI Corporation

In addition to Eyal Talor's purchase, other CVM executives have been buying shares. On the same day as Talor's transaction, Chief Executive Officer Kersten Geert bought 5,192 shares, and Chief Financial Officer Patricia Prichep acquired 4,125 shares, both at $1.04 per share. Earlier, on May 14, 2026, Kersten Geert also bought 300,000 shares at $1.20 each.

Analysts Set New Price Targets

On February 17, 2023, EF Hutton initiated coverage on CVM with a 'buy' rating and set a price target of $10.00. This reflects a positive outlook from analysts, who see potential for significant appreciation in the stock's value.

About CVM

CVM is a biotechnology company focused on developing innovative therapies for various medical conditions. The company is engaged in research and development to bring new treatments to market, aiming to improve patient outcomes. With a team of dedicated scientists and industry professionals, CVM is working towards advancing healthcare solutions.

Bottom Line

The recent insider buying activity at CVM, particularly by Eyal Talor, suggests a vote of confidence from the company's leadership. Institutional investors are also adjusting their positions, reflecting varied strategies. While past performance and insider actions provide insights, it's important for investors to consider the broader market context and company fundamentals when evaluating CVM.